Thalidomide and discoid lupus erythematosus: case series and review of literature.
cutaneous lupus erythematosus
discoid lupus erythematosus
thalidomide
Journal
Drugs in context
ISSN: 1745-1981
Titre abrégé: Drugs Context
Pays: England
ID NLM: 101262187
Informations de publication
Date de publication:
2022
2022
Historique:
received:
07
12
2021
accepted:
03
02
2022
entrez:
4
4
2022
pubmed:
5
4
2022
medline:
5
4
2022
Statut:
epublish
Résumé
The anti-inflammatory drug, thalidomide, is often administered off-label especially in dermatology patients with diseases refractory to different medications. The drug's mechanism of action is not well understood but clinical evidence suggests an immunomodulatory function. Although this drug is a useful tool for several dermatoses, there are associations between its use and neurotoxic and teratogenic side effects. Consequently, it is reserved only for severe and refractory cases. Herein, we present a review about thalidomide focusing on its application in dermatology, particularly on discoid lupus erythematosus (DLE) treatment. We analyzed four cases of people who had a regression of DLE with a dosage of 50 mg thalidomide. Patients were followed to determine the conditions treated with thalidomide, dosage, efficacy, duration of treatment, side effects, adverse events and follow-up. A low dose of 50 mg/day induced a notable and rapid improvement within 1-2 months of treatment and no side effects have been reported so far. We report four cases of DLE treated previously with the most common immunomodulatory agents with no results and finally successfully treated with thalidomide. In all four patients, despite a low dose of 50 mg/day, a notable and rapid improvement was obtained within a few months of treatment with no side effects. Notwithstanding the small cohort size, our experience confirms the efficacy of thalidomide for the treatment of DLE.
Sections du résumé
Background
UNASSIGNED
The anti-inflammatory drug, thalidomide, is often administered off-label especially in dermatology patients with diseases refractory to different medications. The drug's mechanism of action is not well understood but clinical evidence suggests an immunomodulatory function. Although this drug is a useful tool for several dermatoses, there are associations between its use and neurotoxic and teratogenic side effects. Consequently, it is reserved only for severe and refractory cases.
Methods
UNASSIGNED
Herein, we present a review about thalidomide focusing on its application in dermatology, particularly on discoid lupus erythematosus (DLE) treatment. We analyzed four cases of people who had a regression of DLE with a dosage of 50 mg thalidomide. Patients were followed to determine the conditions treated with thalidomide, dosage, efficacy, duration of treatment, side effects, adverse events and follow-up. A low dose of 50 mg/day induced a notable and rapid improvement within 1-2 months of treatment and no side effects have been reported so far.
Results
UNASSIGNED
We report four cases of DLE treated previously with the most common immunomodulatory agents with no results and finally successfully treated with thalidomide. In all four patients, despite a low dose of 50 mg/day, a notable and rapid improvement was obtained within a few months of treatment with no side effects.
Conclusions
UNASSIGNED
Notwithstanding the small cohort size, our experience confirms the efficacy of thalidomide for the treatment of DLE.
Identifiants
pubmed: 35371272
doi: 10.7573/dic.2021-9-8
pii: dic-2021-9-8
pmc: PMC8932252
pii:
doi:
Types de publication
Case Reports
Langues
eng
Informations de copyright
Copyright © 2022 Malara G, Verduci C, Altomonte M, Cuzzola M, Trifirò C, Politi C, Tripepi G.
Déclaration de conflit d'intérêts
Disclosure and potential conflicts of interest: The authors declare that they have no conflicts of interest relevant to this manuscript. The International Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interests form for the authors is available for download at: https://www.drugsincontext.com/wp-content/uploads/2022/02/dic.2021-9-8-COI.pdf
Références
Br J Dermatol. 1983 Apr;108(4):461-6
pubmed: 6838771
Clin Cosmet Investig Dermatol. 2019 Oct 03;12:721-732
pubmed: 31632120
Immunol Today. 1999 Dec;20(12):538-40
pubmed: 10562702
Immunopharmacology. 1995 Nov;31(1):109-16
pubmed: 8655287
Clin Cancer Res. 2007 Feb 15;13(4):1224-31
pubmed: 17317833
Rev Assoc Med Bras (1992). 1998 Oct-Dec;44(4):289-93
pubmed: 9852648
J Am Acad Dermatol. 2014 Mar;70(3):583-4
pubmed: 24528907
Cancer Control. 1999 Oct;6(5):483-495
pubmed: 10758580
Br J Dermatol. 2010 Jan;162(1):91-101
pubmed: 19785596
Ann Pharmacother. 2003 Sep;37(9):1307-20
pubmed: 12921515
Int J Dermatol. 2013 Nov;52(11):1407-9
pubmed: 24164159
Curr Opin Oncol. 2000 Nov;12(6):564-73
pubmed: 11085456
AIDS. 1996 Nov;10(13):1501-7
pubmed: 8931784
J Infect Dis. 1993 Aug;168(2):408-14
pubmed: 8335978
Lepr Rev. 1985 Mar;56(1):35-9
pubmed: 3872986
Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):4082-5
pubmed: 7513432
Ann Rheum Dis. 2012 Nov;71(11):1833-8
pubmed: 22550315
J Exp Med. 1993 Jun 1;177(6):1675-80
pubmed: 8496685
Drug Metab Dispos. 1989 Jul-Aug;17(4):402-5
pubmed: 2571480
J Neurooncol. 1999 Jun;43(2):109-14
pubmed: 10533722
Lupus. 2010 Aug;19(9):1125-36
pubmed: 20693207
Arch Dermatol. 1999 Sep;135(9):1079-87
pubmed: 10490113
J Am Acad Dermatol. 2003 Apr;48(4):548-52
pubmed: 12664018
Pediatr Dermatol. 2001 Mar-Apr;18(2):143-5
pubmed: 11358558
Med Hypotheses. 1997 Aug;49(2):123-31
pubmed: 9278924
J Exp Med. 1998 Jun 1;187(11):1885-92
pubmed: 9607928
J Biochem Mol Toxicol. 2000;14(3):140-7
pubmed: 10711629
Int J Dermatol. 1997 Dec;36(12):881-7
pubmed: 9466191
Clin Cancer Res. 2002 Jun;8(6):1964-73
pubmed: 12060642
Leukemia. 2005 Sep;19(9):1525-31
pubmed: 15973447
Clin Rheumatol. 2016 Jun;35(6):1521-7
pubmed: 27097914
Croat Med J. 2002 Jun;43(3):274-85
pubmed: 12035132
Australas J Dermatol. 2002 Nov;43(4):229-38; quiz 239-40
pubmed: 12423428
Br J Dermatol. 2012 Mar;166(3):616-23
pubmed: 21999437
Arthritis Rheum. 2005 May;52(5):1473-80
pubmed: 15880829
J Clin Oncol. 2000 Jul;18(13):2593-602
pubmed: 10893291
J Invest Dermatol. 1993 Jan;100(1):53S-57S
pubmed: 8423397
Lupus. 2015 Jun;24(7):669-74
pubmed: 25411260
Int Arch Allergy Immunol. 1998 May;116(1):60-6
pubmed: 9623511
Respir Med. 1997 Jan;91(1):31-9
pubmed: 9068814
J Am Acad Dermatol. 2011 Dec;65(6):e195-213
pubmed: 20800319
Int J Womens Dermatol. 2019 Jul 31;5(5):320-329
pubmed: 31909151
An Bras Dermatol. 2014 Jan-Feb;89(1):118-25
pubmed: 24626656
Leuk Res. 2005 Jun;29(6):641-7
pubmed: 15863203
Int J STD AIDS. 1998 Dec;9(12):751-5
pubmed: 9874123
Clin Pharmacol Ther. 1965 May-Jun;6:298-302
pubmed: 14296026
Semin Cutan Med Surg. 1998 Dec;17(4):231-42
pubmed: 9859910
Am J Med. 2005 Mar;118(3):246-50
pubmed: 15745722
N Engl J Med. 1999 Nov 18;341(21):1565-71
pubmed: 10564685
Semin Oncol. 2005 Aug;32(4 Suppl 5):S16-23
pubmed: 16085013
Best Pract Res Clin Rheumatol. 2013 Jun;27(3):391-404
pubmed: 24238695
Ann Intern Med. 2020 Jun 2;172(11):ITC81-ITC96
pubmed: 32479157
Immunopharmacology. 1998 Jul;40(1):11-20
pubmed: 9776474
J Am Acad Dermatol. 1996 Dec;35(6):969-79
pubmed: 8959957
Swiss Med Wkly. 2003 Feb 8;133(5-6):77-87
pubmed: 12644961
J Am Acad Dermatol. 2018 Feb;78(2):342-350.e4
pubmed: 28989111
J Am Acad Dermatol. 2015 Apr;72(4):634-9
pubmed: 25648824
J Eur Acad Dermatol Venereol. 2017 Mar;31(3):389-404
pubmed: 27859683
Am J Med. 2000 Apr 15;108(6):487-95
pubmed: 10781782
J Immunol. 1997 Nov 15;159(10):5157-61
pubmed: 9366446
Proc Natl Acad Sci U S A. 1996 Jul 23;93(15):7552-6
pubmed: 8755512
J Chromatogr. 1987 Jan 23;413:181-7
pubmed: 3558667
Br J Dermatol. 2005 Aug;153(2):254-73
pubmed: 16086735
Lupus. 2008 Apr;17(4):271-3
pubmed: 18413405
Am J Clin Dermatol. 2009;10(6):365-81
pubmed: 19824738
Blood. 2000 Nov 1;96(9):2943-50
pubmed: 11049970